Dehydrotrametenolic acid is primarily studied for its biological activity, particularly in anti-inflammatory and anticancer applications. It has shown inhibitory effects on tumor cell proliferation, making it a compound of interest in cancer research, especially in liver and lung cancer cell lines. The compound also exhibits immunomodulatory properties by suppressing the production of pro-inflammatory mediators such as nitric oxide and cytokines, suggesting potential use in managing inflammatory diseases. Additionally, it has been investigated for its antifibrotic effects, particularly in liver fibrosis models, where it helps reduce collagen deposition and stellate cell activation. Due to these properties, dehydrotrametenolic acid is considered a candidate for developing natural product-based therapeutics in oncology and chronic inflammatory conditions.